Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Common Equity (2017 - 2025)

Historic Common Equity for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to $926.2 million.

  • Denali Therapeutics' Common Equity fell 2975.35% to $926.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $926.2 million, marking a year-over-year decrease of 2975.35%. This contributed to the annual value of $1.2 billion for FY2024, which is 1927.63% up from last year.
  • As of Q3 2025, Denali Therapeutics' Common Equity stood at $926.2 million, which was down 2975.35% from $1.0 billion recorded in Q2 2025.
  • Over the past 5 years, Denali Therapeutics' Common Equity peaked at $1.5 billion during Q1 2024, and registered a low of $811.3 million during Q3 2022.
  • Moreover, its 5-year median value for Common Equity was $1.0 billion (2022), whereas its average is $1.1 billion.
  • Its Common Equity has fluctuated over the past 5 years, first skyrocketed by 11361.52% in 2021, then plummeted by 2975.35% in 2025.
  • Quarter analysis of 5 years shows Denali Therapeutics' Common Equity stood at $962.3 million in 2021, then increased by 8.33% to $1.0 billion in 2022, then fell by 1.1% to $1.0 billion in 2023, then increased by 19.28% to $1.2 billion in 2024, then decreased by 24.68% to $926.2 million in 2025.
  • Its last three reported values are $926.2 million in Q3 2025, $1.0 billion for Q2 2025, and $1.1 billion during Q1 2025.